{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:27:24Z","timestamp":1776065244699,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Gilteritinib received approval for the treatment of FLT3-mutated relapsed or refractory acute myeloid leukemia in Japan in 2018. In accordance with regulatory requirements, we conducted a multicenter, observational surveillance of gilteritinib use in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were followed for 6\u00a0months from gilteritinib treatment initiation. The primary endpoint of the surveillance was incidence of adverse drug reactions related to each element of the safety specification defined in the Japanese Risk Management Plan. This interim analysis presents data collected from 3 December 2018 to 20 September 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 204 patients with case report forms, 107 consented to data publication. Of these 107 patients, 59.8% (n\u00a0=\u00a064) were male and 58.9% (n\u00a0=\u00a063) were aged \u226565\u00a0years; most received a 120-mg\/day initial (80.4%; 86\/107) and maximum (74.8%; 80\/107) daily dose. The discontinuation rate was 61.7% (66\/107); the most common reasons for discontinuation were disease progression (18.7%), transplantation (16.8%) and adverse events (15.0%). The adverse drug reaction rate was 77.6%. The incidences of adverse drug reactions (grade\u00a0\u2265\u00a03) related to each element of the safety specification were myelosuppression, 44.9% (38.3%); liver function disorder, 24.3% (6.5%); infections, 24.3% (21.5%); prolonged QT interval, 10.3% (2.8%); hemorrhage, 9.3% (6.5%); renal dysfunction, 6.5% (0); hypersensitivity, 5.6% (1.9%); interstitial lung disease, 4.7% (3.7%); cardiac failure\/pericarditis\/pericardial effusion, 1.9% (0.9%); pancreatitis, 0.9% (0); posterior reversible encephalopathy syndrome, 0.9% (0.9%). The composite complete remission rate was 62.7%; the 6-month overall survival rate was 77.7%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Gilteritinib treatment for 6\u00a0months in Japan was associated with acceptable efficacy and no new safety concerns were observed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyac069","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:18:22Z","timestamp":1649935102000},"page":"766-773","source":"Crossref","is-referenced-by-count":11,"title":["Interim results from a postmarketing surveillance study of patients with <i>FLT3<\/i>-mutated relapsed\/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan"],"prefix":"10.1093","volume":"52","author":[{"given":"Haruko","family":"Sugamori","sequence":"first","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Lee","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Mitomi","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"2022093018315757500_ref1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113225","article-title":"Advances in acute myeloid leukemia: recently approved therapies and drugs in development","volume":"12","author":"Stanchina","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2022093018315757500_ref2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"key":"2022093018315757500_ref3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"2022093018315757500_ref4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2022093018315757500_ref5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"R\u00f6llig","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022093018315757500_ref6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2022093018315757500_ref7","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/blood-2011-06-363960","article-title":"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation","volume":"119","author":"Man","year":"2012","journal-title":"Blood"},{"key":"2022093018315757500_ref8","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022093018315757500_ref9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.23736\/S0026-4806.20.06989-X","article-title":"FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives","volume":"111","author":"Mosquera Orgueira","year":"2020","journal-title":"Minerva Med"},{"key":"2022093018315757500_ref10","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"2022093018315757500_ref11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"key":"2022093018315757500_ref12","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"2022093018315757500_ref13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40265-019-1062-3","article-title":"Gilteritinib: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"2022093018315757500_ref14","volume-title":"Japan PMDA Approval","author":"Quizartinib"},{"key":"2022093018315757500_ref15","doi-asserted-by":"crossref","first-page":"e1070","DOI":"10.1634\/theoncologist.2019-0976","article-title":"The European Medicines Agency review of gilteritinib (Xospata) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an FLT3 mutation","volume":"25","author":"Tzogani","year":"2020","journal-title":"Oncologist"},{"key":"2022093018315757500_ref16","volume-title":"Prescribing Information","author":"XOSPATA"},{"key":"2022093018315757500_ref17","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022093018315757500_ref18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022093018315757500_ref19","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1111\/cas.13749","article-title":"Clinical profile of gilteritinib in Japanese patients with relapsed\/refractory acute myeloid leukemia: an open-label phase 1 study","volume":"109","author":"Usuki","year":"2018","journal-title":"Cancer Sci"},{"key":"2022093018315757500_ref20","volume-title":"[Prescribing Information]","author":"XOSPATA"},{"key":"2022093018315757500_ref21","volume-title":"Xospata New Drug Application FDA Multisciplinary Review"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/7\/766\/46215053\/hyac069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/7\/766\/46215053\/hyac069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T19:47:39Z","timestamp":1664567259000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/52\/7\/766\/6581997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,5,6]]},"published-print":{"date-parts":[[2022,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac069","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2022,5,6]]}}}